andy,i typed mesenchymal precursor cells into pubmed and turned up 1052 results.
Msb is a work in progress ,its difficult to make assumptions based on trials involving 100 or so patients hence the need for phase 3 trials (1500 patients ).
My understanding is that there will be publications and there will be peer reviews.
I believe that the share price accurately reflects these processes and that's why the company is values 1.6 bil and not 20 bil.
i value your thoughts and yet my view is that there is enough on the table now to warrant a punt on the prof and his team
inFact ,and for the record , "I'M ALL IN !!".
GO U GOOD THING !!!!!
(FELLOW MESOPHILES PLEASE DYOR!!!!!!)
GO THE SWANS!!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.36 |
Change
0.080(3.51%) |
Mkt cap ! $2.995B | |||
| Open | High | Low | Value | Volume |
| $2.31 | $2.39 | $2.30 | $5.446M | 2.312M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 54392 | $2.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.37 | 23563 | 14 |
View Market Depth
| Last trade - 11.09am 23/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |